Clinical Trials in Tennessee

Showing 2721-2740 of 9,675 trials

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

NCT02437136

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanoma, and Mismatch-Repair Proficient CRC.

Non-Small Cell Lung CancerMelanomaMismatch Repair-Proficient Colorectal Cancer

Syndax Pharmaceuticals191 participantsStarted Aug 2015

New Haven, Connecticut, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPhase 129 miles

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Multiple Myeloma

Pfizer101 participantsStarted Nov 2017

Encinitas, California, United States • La Jolla, California, United States • La Jolla, California, United States +34 more locations

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Find Trials by Condition in Tennessee

Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

BIOTRONIK Conduction System Pacing With the Solia Lead

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Study of LY3561774 in Participants With Mixed Dyslipidemia

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Patient Reported Outcomes With WaveLight LASIK

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

A Study of JR-171 in Patients With Mucopolysaccharidosis I